London 2014 Registration Visa Letters Programme Satellite Meetings Glaucoma Day 2014 Exhibition Hotel Booking Virtual Exhibition Star Alliance
london escrs

Course handouts are now available
Click here


Come to London

video-icon

WATCH to find out why


Site updates:

Programme Updates. Programme Overview and - Video Symposium on Challenging Cases now available.


Phakic intraocular lens Visian with central flow technology: up to 2 years

Search Abstracts by author or title
(results will display both Free Papers & Poster)

Session Details

Session Title: Posterior chamber Phakic IOLS for correction of Myopia

Session Date/Time: Monday 15/09/2014 | 08:00-10:30

Paper Time: 08:30

Venue: Capital Hall B

First Author: : J.Fernández Pérez SPAIN

Co Author(s): :    A. Valero Marcos   J. Jiménez Velázquez   F. Martínez Peña        

Abstract Details

Purpose:

To evaluate the efficacy, predictability, security and stability of a posterior chamber Implantable Collamer Lens phakic intraocular lens (ICL) with a central flow design (Visian V4C) to correct myopia after two years of follow up.

Setting:

Department of Ophthalmology, Q Vision, Vithas Vírgen del Mar Hospital, Almería (Spain).

Methods:

Series of cases in which myopic patients who were implanted a spherical phakic lens Visian V4C with a central flow design of aqueous humor through its central hole were included; avoiding the need of iridotomy. In all patients included, uncorrected (UDVA) and corrected visual acuity (CDVA), refraction, spherical equivalent, mean pachymetry, intraocular pressure (IOP), the endothelial cell count, the anterior chamber depth (ACD) and the sulcus - sulcus distance were measured. After surgery, the uncorrected and corrected visual acuity, refraction, spherical equivalent, intraocular pressure, endothelial cell count and complications were evaluated in a month, 6 months, a year and 2 years.

Results:

This study involved 39 patients (63 eyes) with a mean age of 31.8 ± 7.05 years (range 19-46 years). The mean postoperative spherical equivalent was (-0.12 ± 0.22) dioptres per month and it was constant throughout the follow-up. The UDVA in 60 % of eyes remained off the preoperative CDVA, 24 % of eyes gained one line and 16% gained two or more lines. About IOP, 30% of the eyes had a decrease of 1 mm Hg, 40% was constant, 20% increase in 1 mm Hg and 10% at 2 mm Hg. The endothelial cell count showed no statistically significant losses. There was no postoperative complication, no need to explant or replacement of the lens.

Conclusions:

Visian ICL lens V4C is useful for a effective correcting moderate and high myopia, predictable, safe and stable manner.

Financial Interest:

NONE

Back to previous